|
“Safety and effectiveness study of autologous natural killer and natural killer t cells on cancer” including HCC
|
Phase I
|
NK cell and NKT cell-based autologous adoptive immunotherapy
|
Suspended
|
NCT00909558
|
|
“Evaluate the efficacy and safety of MG4101 (ex vivo expanded allogeneic NK cell)”
|
Phase 2
|
NK cell transfer after curative liver resection on the patient with advanced HCC
|
Completed
|
NCT02008929
|
|
By using adoptive transfer of autologous NK cells to prevent recurrence of hepatocellular carcinoma after curative therapy
|
Phase 2
|
Adjuvant adoptive immune therapy using NK cell in patient undergone curative resection (RFA or operation)
|
Not yet recruiting
|
NCT02725996
|
|
Safety study of NK cells from sibship to treat the recurrence of HCC after liver transplantation
|
Phase 1
|
Conventional treatment and NK cell transfer
|
Recruiting
|
NCT02399735
|
|
A study of MG4101 (allogeneic natural killer cell) for intermediate-stage of hepatocellular carcinoma
|
Phase 2
|
Allogeneic natural killer cell transfer after transarterial chemoembolization
|
Recruiting
|
NCT02854839
|
|
Safety study of liver natural killer cell therapy for hepatoma liver transplantation (MIAMINK)
|
Phase 1
|
Liver transplantation and liver NK cell inoculation
|
Completed
|
NCT01147380
|
|
Recombinant vesicular stomatitis virus expressing IFN-β and probable exertion of anti-tumor activity of NK cells against adult HCC
|
Phase I
|
Cytokine therapy
|
Recruiting
|
NCT01628640
|
